UAE
Bahrain
Jordan
Kuwait
Oman
Qatar
Saudi ArabiaHealth News
New Eliquis® (apixaban) post-hoc subanalysis of the Phase III ARISTOTLE trial
Date: Sep-03-2013Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) has announced results of a post-hoc subanalysis from the Phase III ARISTOTLE trial. Patients with nonvalvular atrial fibrillation (NVAF) who are anticoagulated to reduce the risk of stroke often undergo procedures for which temporary discontinuation of the anticoagulant prior to and following the procedure is sometimes warranted...
Mass screening identifies untreated AF in 5% of 75-76 year olds
Date: Sep-03-2013Stroke is the second cause of death worldwide. Atrial fibrillation is the most common clinically relevant cardiac arrhythmia in Europe, affecting approximately 1.5-2% of the general population.[1] Prevalence is estimated to double in the next 50 years as the population ages. Patients with atrial fibrillation have a five-fold increased risk of ischaemic stroke even though around 30% have no symptoms. As blood is less adequately shifted from the heart during atrial fibrillation, blood clots can form and cause large ischaemic strokes...
CHADS2 risk score assigns over one-third of stroke patients to low or intermediate stroke risk
Date: Sep-03-2013In contrast, a CHA2DS2-VASc score of 0 identifies a subgroup of patients with very low stroke risk unlikely to benefit from anticoagulation treatment. Professor Nabauer said: "AF is the most frequent cardiac arrhythmia requiring hospitalisation and has a 1-2% prevalence in the general population. AF is associated with a significant risk of stroke with frequently disabling consequences. While oral anticoagulation is very effective in preventing ischaemic strokes in AF, it increases bleeding risk...
Statins lower risk of cataracts
Date: Sep-03-2013Cataracts are the leading cause of visual impairment worldwide affecting more than 20 million people. Statins are among the most commonly prescribed medications. In the USA they are prescribed to 1 in 3 people over 45 years of age at a cost of $35 billion annually. Professor Kostis said: "There is persistent concern among physicians and other health care providers about the possible cataractogenicity of statins.[1] We therefore investigated the relationship of statins and cataracts in a meta-analysis of 14 studies selected after detailed review of the medical literature...
High dose statins prevent dementia
Date: Sep-03-2013Dr Lin said: "Statins are widely used in the older population to reduce the risk of cardiovascular disease. But recent reports of statin-associated cognitive impairment have led the US Food and Drug Administration (FDA) to list statin-induced cognitive changes, especially for the older population, in its safety communications." He added: "Previous studies had considered statin therapy to exert a beneficial effect on dementia. But few large-scale studies have focused on the impact of statins on new-onset, non-vascular dementia in the geriatric population...
Reimbursement systems influence achievement of cholesterol targets
Date: Sep-03-2013Dr Gitt said: "There are wide variations between European countries in the achievement of LDL-cholesterol (LDL-C) targets. However the effect of different reimbursement systems on meeting the targets was unknown." Between June 2008 and February 2009 DYSIS assessed the prevalence and types of persistent lipid abnormalities in patients receiving statins. Eligible patients were at high risk of a cardiovascular event, aged 45 years, and had been on chronic statin treatment for at least three months...
Violent behavior linked to nutritional deficiencies
Date: Sep-03-2013Deficiencies of vitamins A, D, K, B1, B3, B6, B12 and folate, and of minerals iodine, potassium, iron, magnesium, zinc, chromium and manganese can all contribute to mental instability and violent behavior, according to a report published in the Spring 2013 issue of Wise Traditions, the journal of the Weston A. Price Foundation. The article, Violent Behavior: A Solution in Plain Sight by Sylvia Onusic, PhD, CNS, LDN, seeks reasons for the increase in violent behavior in America, especially among teenagers...
Statins reduce CV events in coronary artery disease patients with very low LDL-C
Date: Sep-03-2013Dr Nakano said: "Many randomised clinical trials, such as Treating to New Targets (TNT) and PROVE IT-TIMI, have shown that aggressive cholesterol lowering with statins improves clinical outcomes in patients with coronary artery disease (CAD) and high LDL-C levels.[1,2] But until now it was not known whether aggressive lipid lowering with statins would also benefit CAD patients with very low LDL-C levels...
Study demonstrates homeopathic Traumeel® as effective treatment option for musculoskeletal disorders
Date: Sep-03-2013A recent study shows that Traumeel®, a topical pain medicine made of 12 natural ingredients (out of 14 actives), is as effective as a current standard therapy, 1% diclofenac gel, in reducing pain and improving function in adults with ankle sprain injuries. The findings, from the Traumeel® in Acute Ankle Sprain Study (TAASS), were recently highlighted in the online International Journal of Clinical Practice as well as an issue of Current Medical Research and Opinion,[1] and first reported at the European League Against Rheumatism (EULAR) conference in June 2012...
Mycobacterium tuberculosis: Our African follower for over 70,000 years!
Date: Sep-03-2013Tuberculosis (TB) remains one of deadliest infectious diseases of humans, killing 50% of individuals when left untreated. Even today, TB causes 1-2 million deaths every year mainly in developing countries. Multidrug-resistance is a growing threat in the fight against the disease. An international group of researchers led by Sebastien Gagneux from the Swiss Tropical and Public Health Institute (Swiss TPH) has now identified the origin in time and space of the disease...
Stay Connected
